<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209855</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN853-0416</org_study_id>
    <secondary_id>2019-003509-80</secondary_id>
    <nct_id>NCT04209855</nct_id>
  </id_info>
  <brief_title>A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</brief_title>
  <acronym>MIRASOL</acronym>
  <official_title>MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groupbs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab&#xD;
      soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant&#xD;
      high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose&#xD;
      tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator,&#xD;
      appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha&#xD;
      (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to either mirvetuximab soravtansine (MIRV) or Investigator's&#xD;
      Choice chemotherapy (paclitaxel, PEGylated liposomal doxorubicin, or topotecan).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from date of randomization until Investigator-assessed progressive disease or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events (AEs) will be evaluated according to the NCI CTCAE v5.0. AEs will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective response includes best response of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from date of randomization until the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patient-reported outcomes</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of patients achieving at least 15 point absolute improvement at Week 8 or Week 9 in the abdominal/GI scale of the European Organization for Research and Treatment of Cancer (EORTC) ovarian cancer specific quality of life questionnaire (QLQ-OV28). A higher score represents a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from initial response until Investigator-assessed progressive disease for all patients who achieve a confirmed objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum CA-125 response determined using the GCIG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival 2 (PFS 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from date of randomization until second disease progression or death whichever occurs first. Results will be summarized by arm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-reported outcomes using EORTC QLQ-C30 questionnaires</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The EORTC QLQ-C30 questionnaires will be used to collect data on the patient's functioning, health-related QOL, disease symptoms and health status. A higher score represents a higher response level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-reported outcomes using EQ-5D-5L questionnaires</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The EuroQol-5 Dimension 5-level (EQ-5D-5L) questionnaires will be used to collect data on the patient's functioning, health-related QOL, disease symptoms and health status. A higher score represents a higher response level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Plasma samples will be collected to determine the concentration of MIRV (antibody-drug conjugate, total antibody, free DM4, S-methyl DM4 and possibly other metabolites). Summary statistics of the concentration at each time point (nominal time) will be presented. Graphical presentation of the data may also be completed using nominal time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The presence of anti-drug antibodies to mirvetuximab soravtansine</description>
  </other_outcome>
  <other_outcome>
    <measure>Identification of soluble FRα levels and other biomarkers</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>mirvetuximab soravtansine (MIRV; IMGN853)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle&#xD;
Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)&#xD;
Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvetuximab Soravtansine</intervention_name>
    <description>Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.</description>
    <arm_group_label>mirvetuximab soravtansine (MIRV; IMGN853)</arm_group_label>
    <other_name>MIRV</other_name>
    <other_name>IMGN853</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is a taxane that can stabilize microtubules to inhibit cell division. It was approved for treatment of recurrent epithelial ovarian cancer.</description>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Topotecan induces irreversible DNA damage. It inhibits topoisomerase 1, leading to both single and double strand DNA break that eventually promote apoptosis. Topotecan was approved for treatment of epithelial ovarian cancer after failure of initial or subsequent chemotherapy.</description>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>Pegylated liposomal doxorubicin is a standard chemotherapy regimen used for treating platinum-resistant ovarian cancer. The active component doxorubicin is an anthracycline that intercalates DNA, leading to inhibition of replication and subsequently, the inhibition of proper cell division.</description>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients ≥ 18 years of age&#xD;
&#xD;
          2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian&#xD;
             cancer, primary peritoneal cancer, or fallopian tube cancer&#xD;
&#xD;
          3. Patients must have platinum-resistant disease (defined as progression within 6 months&#xD;
             from completion of a minimum of four cycles of platinum-containing therapy) Note: This&#xD;
             should be calculated from the date of the last administered dose of platinum therapy&#xD;
             to the date of the radiographic imaging showing progression. Patients who are&#xD;
             platinum-refractory during front-line treatment are excluded&#xD;
&#xD;
          4. Patients must have progressed on or after their most recent line of therapy Note:&#xD;
             Progression must be determined radiographically and/or by CA-125 GCIG progression&#xD;
             criteria&#xD;
&#xD;
          5. Patients must be willing to provide an archival tumor tissue block or slides, or&#xD;
             undergo procedure to obtain a new biopsy using a low risk, medically routine procedure&#xD;
             for IHC confirmation of FRα positivity&#xD;
&#xD;
          6. Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1&#xD;
             (FOLR-2.1) CDx assay&#xD;
&#xD;
          7. Patients must have at least one lesion that meets the definition of measurable disease&#xD;
             by RECIST v1.1 (radiologically measured by the Investigator)&#xD;
&#xD;
          8. Patients must have received at least 1 but no more than 3 prior systemic lines of&#xD;
             anticancer therapy, and for whom single-agent therapy is appropriate as the next line&#xD;
             of treatment:&#xD;
&#xD;
               1. Adjuvant ± neoadjuvant considered one line of therapy&#xD;
&#xD;
               2. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered as part&#xD;
                  of the preceding line of therapy (ie, not counted independently)&#xD;
&#xD;
               3. Therapy changed due to toxicity in the absence of progression will be considered&#xD;
                  as part of the same line (ie, not counted independently)&#xD;
&#xD;
               4. Hormonal therapy will be counted as a separate line of therapy unless it was&#xD;
                  given as maintenance&#xD;
&#xD;
          9. Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)&#xD;
             of 0 or 1&#xD;
&#xD;
         10. Time from prior therapy:&#xD;
&#xD;
               1. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)&#xD;
&#xD;
               2. Focal radiation completed at least 2 weeks prior to first dose of study drug&#xD;
&#xD;
         11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior&#xD;
             therapy-related toxicities&#xD;
&#xD;
         12. Major surgery must be completed at least 4 weeks prior to first dose and have&#xD;
             recovered or stabilized from the side effects of prior surgery&#xD;
&#xD;
         13. Patients must have adequate hematologic, liver and kidney functions defined as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500/μL)&#xD;
&#xD;
               2. Platelet count ≥ 100 x 109/L (100,000/μL) without platelet transfusion in the&#xD;
                  prior 10 days&#xD;
&#xD;
               3. Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN&#xD;
&#xD;
               6. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert&#xD;
                  syndrome are eligible if total bilirubin &lt; 3.0 x ULN&#xD;
&#xD;
               7. Serum albumin ≥ 2 g/dL&#xD;
&#xD;
         14. Patients or their legally authorized representative must be willing and able to sign&#xD;
             the informed consent form (ICF) and to adhere to the protocol requirements&#xD;
&#xD;
         15. Women of childbearing potential (WCBP) must agree to use highly effective&#xD;
             contraceptive method(s) (as defined in Section 5.9.6 in the protocol) while on study&#xD;
             drug and for at least 3 months after the last dose of MIRV or at least 6 months after&#xD;
             the last dose of paclitaxel, pegylated liposomal doxorubicin, or topotecan&#xD;
&#xD;
         16. WCBP must have a negative pregnancy test within 4 days prior to the first dose of&#xD;
             study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed&#xD;
             tumors containing any of the above histologies, or low-grade or borderline ovarian&#xD;
             tumor&#xD;
&#xD;
          2. Patients with primary platinum-refractory disease, defined as disease that did not&#xD;
             respond to or has progressed within 3 months of the last dose of first line&#xD;
             platinum-containing chemotherapy&#xD;
&#xD;
          3. Patients with prior wide-field RT affecting at least 20% of the bone marrow&#xD;
&#xD;
          4. Patients with &gt; Grade 1 peripheral neuropathy per CTCAE v5.0&#xD;
&#xD;
          5. Patients with active or chronic corneal disorders, history of corneal transplantation,&#xD;
             or active ocular conditions requiring ongoing treatment/monitoring such as&#xD;
             uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal&#xD;
             injections, active diabetic retinopathy with macular edema, macular degeneration,&#xD;
             presence of papilledema, and /or monocular vision&#xD;
&#xD;
          6. Patients with serious concurrent illness or clinically relevant active infection,&#xD;
             including, but not limited to the following:&#xD;
&#xD;
               1. Active hepatitis B or C infection (whether or not on active antiviral therapy)&#xD;
&#xD;
               2. HIV infection&#xD;
&#xD;
               3. Cytomegalovirus infection&#xD;
&#xD;
               4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks&#xD;
                  before starting study drug&#xD;
&#xD;
          7. Patients with history of multiple sclerosis or other demyelinating disease and/or&#xD;
             Lambert-Eaton syndrome (paraneoplastic syndrome)&#xD;
&#xD;
          8. Patients with clinically significant cardiac disease including, but not limited to,&#xD;
             any one of the following:&#xD;
&#xD;
               1. Myocardial infarction ≤ 6 months prior to first dose&#xD;
&#xD;
               2. Unstable angina pectoris&#xD;
&#xD;
               3. Uncontrolled congestive heart failure (New York Heart Association &gt; class II)&#xD;
&#xD;
               4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)&#xD;
&#xD;
               5. Uncontrolled cardiac arrhythmias&#xD;
&#xD;
          9. Patients assigned to PLD stratum only: Left ventricular ejection fraction (LVEF) below&#xD;
             the institutional limit of normal as measured by echocardiography (ECHO) or multigated&#xD;
             acquisition (MUGA) scan&#xD;
&#xD;
         10. Patients with a history of hemorrhagic or ischemic stroke within six months prior to&#xD;
             randomization&#xD;
&#xD;
         11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)&#xD;
&#xD;
         12. Patients with a previous clinical diagnosis of non-infectious interstitial lung&#xD;
             disease (ILD), including noninfectious pneumonitis&#xD;
&#xD;
         13. Patients with required use of folate-containing supplements (eg, folate deficiency)&#xD;
&#xD;
         14. Patients with prior hypersensitivity to monoclonal antibodies&#xD;
&#xD;
         15. Women who are pregnant or lactating&#xD;
&#xD;
         16. Patients with prior treatment with MIRV or other FRα-targeting agents&#xD;
&#xD;
         17. Patients with untreated or symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
         18. Patients with a history of other malignancy within 3 years prior to randomization.&#xD;
             Note: does not include tumors with a negligible risk for metastasis or death (eg,&#xD;
             adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or&#xD;
             carcinoma in situ of the cervix or breast&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Method, MPH, MBA</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ImmunoGen, Inc.</last_name>
    <phone>781-895-0600</phone>
    <email>medicalaffairs@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB) GYN Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Reeves</last_name>
      <phone>205-996-2782</phone>
      <email>greeves@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Leath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alaska Women's Cancer Care</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Fulcher</last_name>
      <phone>907-562-4673</phone>
      <email>Christina.Fulcher@providence.org</email>
    </contact>
    <investigator>
      <last_name>Melissa Hardesty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL - USOR</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Beers</last_name>
      <phone>602-277-4868</phone>
      <email>wendy.beers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Monk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Heeney</last_name>
      <phone>480-342-6004</phone>
      <email>Heeney.Ashley@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kristina Butler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Kristina Butler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Robertson</last_name>
      <phone>520-886-0206</phone>
      <email>linda.robertson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Weiss</last_name>
      <phone>520-694-9071</phone>
      <email>bweiss@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Setsuko Chambers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaushali Thakone-Shah</last_name>
      <phone>310-794-9652</phone>
      <email>KThakoreShah@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gottfried Konecny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Cancer Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atessa Kiani</last_name>
      <phone>949-764-6586</phone>
      <email>atessa.kiani@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Mendivil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Bigay</last_name>
      <phone>415-514-6725</phone>
      <email>katherine.bigay@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Edwin Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olive View - UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Alcantar</last_name>
      <phone>747-210-4529</phone>
      <email>bialcantar@dhs.lacounty.gov</email>
    </contact>
    <investigator>
      <last_name>Mae Zakhour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oncology Clinical Trials</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bedford</last_name>
      <phone>707-651-5213</phone>
      <email>amy.j.bedford@kp.org</email>
    </contact>
    <investigator>
      <last_name>Ramey Littell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Dollarhide</last_name>
      <phone>303-430-2700</phone>
      <email>susan.dollarhide@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ling Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Baker</last_name>
      <phone>203-785-6398</phone>
      <email>lisa.baker@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Alessandro Santin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist South Division</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Cowan</last_name>
      <phone>239-274-9930</phone>
      <phone_ext>9893</phone_ext>
      <email>pcowan@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Lowell Hart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennica Eurillo</last_name>
      <phone>904-953-3897</phone>
      <email>Eurillo.Jennica@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Gerardo Colon-Otero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Care Florida / Women's Cancer Associates</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Whitaker</last_name>
      <phone>727-826-0792</phone>
      <email>awhitaker@womenscarefl.com</email>
    </contact>
    <investigator>
      <last_name>Megan D. Indermaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist North Division</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinah Welsh-Barnes</last_name>
      <phone>727-216-1143</phone>
      <phone_ext>13097</phone_ext>
      <email>diBarnes@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Gail Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Hill</last_name>
      <phone>941-917-8789</phone>
      <email>sharon-hill@smh.com</email>
    </contact>
    <investigator>
      <last_name>James Fiorica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist East Division</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Brouda</last_name>
      <phone>561-366-4100</phone>
      <phone_ext>14754</phone_ext>
      <email>ibrouda@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Spitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Morgan</last_name>
      <phone>912-350-7878</phone>
      <email>lisa.morgan2@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>James Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Glidden</last_name>
      <phone>847-259-4482</phone>
      <email>andrea.glidden@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Urszula Sobol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penelope Dolan</last_name>
      <phone>773-702-3394</phone>
      <email>pdolan@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Moroney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Sudarshan K. Sharma, Ltd.</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peg Gregus</last_name>
      <phone>630-601-7719</phone>
      <email>drsharma@ameritech.net</email>
    </contact>
    <investigator>
      <last_name>Sharma Sudarshan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Health Network</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Nungester</last_name>
      <phone>317-621-0405</phone>
      <email>BNungester@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Sonnenburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reshma Honaker</last_name>
      <phone>913-588-7756</phone>
      <email>rjaseja@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Dixon</last_name>
      <phone>859-301-5473</phone>
      <email>Becky.Dixon@stelizabeth.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Schuler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslye Adams</last_name>
      <phone>502-899-3366</phone>
      <phone_ext>19230</phone_ext>
      <email>Leslye.Adams@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Mary Gordinier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochnser Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Breaux</last_name>
      <phone>504-842-4478</phone>
      <email>mbreaux@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Katrina Wade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WK Physicians Network/Gynecologic Oncology Associates</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>771103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Kay</last_name>
      <phone>318-212-8130</phone>
      <email>ckay@wkhs.com</email>
    </contact>
    <investigator>
      <last_name>Destin Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyudmila Kalnitskaya</last_name>
      <phone>301-754-7552</phone>
      <email>kalnitsl@holycrosshealth.org</email>
    </contact>
    <investigator>
      <last_name>James Barter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imaan Khan</last_name>
      <phone>301-942-9220</phone>
      <email>imaan.khan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cheryl Aylesworth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dinh</last_name>
      <phone>617-636-8885</phone>
      <email>mdinh1@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>John Schorge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sorci</last_name>
      <phone>413-794-3188</phone>
      <email>Laura.Sorci@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Tashanna Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Pepka-Jones</last_name>
      <phone>508-334-1160</phone>
      <email>Dawn.Pepka-Jones@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Susan Zweizig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Velfling</last_name>
      <phone>734-712-4950</phone>
      <email>Christina.Velfling@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Rebecca Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Wolgast</last_name>
      <phone>313-576-8994</phone>
      <email>wolgasta@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Robert Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle Johnson</last_name>
      <phone>507-422-6892</phone>
      <email>Johnson.Janelle1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Saravut J Weroha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rabenn</last_name>
      <phone>651-735-7414</phone>
      <email>anne.rabenn@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jessica Thomes-Pepin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Kansas City/ Sarah Cannon</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela McCann</last_name>
      <phone>913-498-7892</phone>
      <email>pamela.mccann@hcamidwest.com</email>
    </contact>
    <investigator>
      <last_name>Kristopher LyBarger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Leigland</last_name>
      <phone>406-731-8222</phone>
      <email>KerstinLeigland@Benefis.org</email>
    </contact>
    <investigator>
      <last_name>Grant Harrer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center of Hope</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Pierpoint</last_name>
      <phone>775-327-4673</phone>
      <email>spierpoint@cohreno.com</email>
    </contact>
    <investigator>
      <last_name>Peter Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital, Inc</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasey Bessada</last_name>
      <phone>201-634-5792</phone>
      <email>kbessad@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Eleonora Teplinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa VanOrden</last_name>
      <phone>201-541-6312</phone>
      <email>mvanorden@holyname.org</email>
    </contact>
    <investigator>
      <last_name>Sharyn Lewin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Vattakalam</last_name>
      <phone>212-342-6895</phone>
      <email>rmv2110@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth of the Carolinas Outpatient Cancer Center</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Mason</last_name>
      <phone>910-715-2213</phone>
      <email>pmason@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Sundborg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: OHC - Oncology_Hematology Care Clinical Trials, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Clary</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27124</phone_ext>
      <email>nicole.clary1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cynthia Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Runner</last_name>
      <phone>216-778-8306</phone>
      <email>krunner@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Kimberly Resnick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna White</last_name>
      <phone>216-444-3414</phone>
      <email>whited11@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Peter Rose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus NCORP</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Collins</last_name>
      <phone>614-488-2637</phone>
      <email>pam@columbusccop.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Dodd</last_name>
      <phone>614-366-9084</phone>
      <email>Kelly.Dodd@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Casey Cosgrove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cooper</last_name>
      <phone>405-271-8001</phone>
      <email>Sarah-Cooper@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell</last_name>
      <phone>918-505-3304</phone>
      <email>melissa.powell@ocsri.org</email>
    </contact>
    <investigator>
      <last_name>Michael Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Salter</last_name>
      <phone>541-683-5001</phone>
      <email>luisa.salter@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Gynecologic Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Elliott</last_name>
      <phone>503-413-8199</phone>
      <email>lelliott@lhs.org</email>
    </contact>
    <investigator>
      <last_name>Colleen McCormick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Kern</last_name>
      <phone>360-597-1316</phone>
      <email>Julian.Kern@compassoncology.com</email>
    </contact>
    <investigator>
      <last_name>Erin Salinas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Elkins</last_name>
      <phone>215-615-6740</phone>
      <email>Katie.Elkins@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lainie Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reshma Shelat</last_name>
      <phone>215-214-1753</phone>
      <email>Reshma.Shelat@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Gina Mantia-Smaldone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital-UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steeleb@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Lan Coffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Baldauf</last_name>
      <phone>412-578-4517</phone>
      <email>erin.baldauf@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Crafton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann John</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48181</phone_ext>
      <email>ajohn@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Lokich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology / Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Long</last_name>
      <phone>615-329-7477</phone>
      <email>kristy.long@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology-South Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Janeczko</last_name>
      <phone>512-447-2202</phone>
      <email>patricia.janeczko@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Teneriello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Morris</last_name>
      <phone>817-413-1500</phone>
      <email>tina.morris@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Noelle Cloven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Robazetti</last_name>
      <phone>713-500-6382</phone>
      <email>sonia.c.robazetti@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Lucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - McAllen South Second</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereida Salinas</last_name>
      <phone>956-969-0021</phone>
      <email>nereida.salinas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Suresh Ratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Ponce</last_name>
      <phone>210-595-5300</phone>
      <email>debbie.ponce@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Santillan-Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology, P.A.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Howell</last_name>
      <phone>281-276-3413</phone>
      <email>melissa.howell@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kristy Ward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - The Woodlands, Gynecologic Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>281-296-0365</phone>
      <email>ruth.lopez1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christine Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Shelly Maxfield</last_name>
      <phone>903-579-9801</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology, P.A.</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Gray</last_name>
      <phone>281-332-7505</phone>
      <email>Tara.Gray@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Terri Pustilnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
      <email>am7bd@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Virginia Cancer Specialists, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jutta McGovern</last_name>
      <phone>571-222-2200</phone>
      <email>jutta.mcgovern@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Robert Marsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology &amp; Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Brumbaugh</last_name>
      <phone>509-783-4637</phone>
      <email>Corey.Brumbaugh@kadlec.org</email>
    </contact>
    <investigator>
      <last_name>Zhuo Ying</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University- MBRCC</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Moore</last_name>
      <phone>304-293-0609</phone>
      <email>deborah.moore@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Valerie Galvan-Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Fischer</last_name>
      <phone>(02) 4941 8718</phone>
      <email>Clare.Fischer@healthscope.com.au</email>
    </contact>
    <investigator>
      <last_name>Antonino Bonaventura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Osmond</last_name>
      <phone>(02) 9382 5130</phone>
      <email>Danielle.Osmond@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Yeh Chen Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Webster</last_name>
      <phone>61 3 8572 2393</phone>
      <email>Elizabeth.Webster@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kate Webber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Clinics Victoria (OCV) - Cabrini Malvern Hospital Location</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle Woods</last_name>
      <phone>613 9508 3437</phone>
      <email>rwoods@cabrini.com.au</email>
    </contact>
    <investigator>
      <last_name>Gary Richardson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Sultana</last_name>
      <phone>02 94631363</phone>
      <email>Yasmin.Sultana@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Sally Baron Hay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Burnside War Memorial Hospital - The Brian Fricker Oncology Centre</name>
      <address>
        <city>Toorak Gardens</city>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Caruso</last_name>
      <phone>61 8 8202 7222</phone>
      <email>dcaruso@burnsidehospital.asn.au</email>
    </contact>
    <investigator>
      <last_name>Martin Oehler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wachtelaer</last_name>
      <phone>+ 0032 53 72 86 56</phone>
      <email>stephanie.wachtelaer@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Huygh Greet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2390</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Tanasale</last_name>
      <phone>00 32 3 650 53 97 / 508 5153</phone>
      <email>Laura.Tanasale@klina.be</email>
    </contact>
    <investigator>
      <last_name>Wim Demey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ St-Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robrecht Timmerman</last_name>
      <phone>+ 003292245295</phone>
      <email>robrecht.timmerman@azstlucas.be</email>
    </contact>
    <investigator>
      <last_name>Vincent Renard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mieke Verrecas</last_name>
      <phone>+32 16 34 17 64</phone>
      <email>mieke.verrecas@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Toon Van Gorp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Georgieva</last_name>
      <phone>+359 878 993 160</phone>
      <email>svetlana.georgieva@acibademcityclinic.bg</email>
    </contact>
    <investigator>
      <last_name>Jeliazko Arabadjiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sv. Ivan Rilski&quot;, EAD, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Ferdinandova</last_name>
      <phone>+359888699136</phone>
      <email>stefanova.yolanta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bozhil Robev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Meyer</last_name>
      <phone>403-521-3301</phone>
      <email>Kelsey.Meyer@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Prafull Ghatage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Churchill</last_name>
      <phone>780-577-8029</phone>
      <email>wanda.churchill@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Sophia Pin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Christink</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70308</phone_ext>
      <email>kchristink@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Johanne Weberpals</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nithla Mohanathas</last_name>
      <phone>416-480-5000</phone>
      <phone_ext>x85838</phone_ext>
      <email>nithla.mohanathas@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Allan Covens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Chow</last_name>
      <phone>416-634-8013</phone>
      <email>anna.chow@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Amit Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong-Nam (Nathalie) Nguyen</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>31975</phone_ext>
      <email>phuong-nam.nguyen@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Lucy Gilbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Universite de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Tremblay</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>30637</phone_ext>
      <email>josee.tremblay.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Bourbonnais</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>12890</phone_ext>
      <email>annie.bourbonnais.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Paul Bessette</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Jadlovcova</last_name>
      <phone>+420597371303</phone>
      <email>lucie.jadlovcova@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Klat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Všeobecná fakultní nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 51</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Stribrna</last_name>
      <phone>420,224,969,732</phone>
      <email>jana.stribrna@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>David Cibula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KNTB a.s. Zlín</name>
      <address>
        <city>Zlín</city>
        <zip>762 75</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Mašláňová</last_name>
      <phone>00 420 577 552 366</phone>
      <email>maslanova@bnzlin.cz</email>
    </contact>
    <investigator>
      <last_name>Marketa Pospiskova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clémence LE BBERVET</last_name>
      <phone>+ 33531155101</phone>
      <email>LeBervet.clemence@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Gladieff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Cedex B.P 307</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude-Angela Geoffray</last_name>
      <phone>+33 320295569</phone>
      <email>c-geoffray@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Stephanie Becourt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'ouest, site Angers</name>
      <address>
        <city>Angers</city>
        <state>Cedex</state>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit SEMELIN</last_name>
      <phone>+33241352775</phone>
      <email>benoit.semelin@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Abadie-Lacourtoisie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ophélie Sivignon</last_name>
      <phone>+ 33 3 81 66 81 66</phone>
      <email>osivignon@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Elsa Kalbacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Chouaib</last_name>
      <phone>+33(0) 524 071 948</phone>
      <email>n.chouaib@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Floquet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DJEDOUI Ibtissame</last_name>
      <phone>+33 478782644</phone>
    </contact>
    <contact_backup>
      <last_name>Ibtissame.DJEDOUI@lyon.unicancer.fr</last_name>
    </contact_backup>
    <investigator>
      <last_name>Olivier Tredan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Lombardi</last_name>
      <phone>33 4 91 22 30 59</phone>
      <email>LOMBARDIA@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sabatier Renaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisele Pina</last_name>
      <phone>+33 01 58 41 17 74</phone>
      <email>gisele.pina@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jerome Alexandre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75960 Cedex 20</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Branco</last_name>
      <phone>+33 1.44.64.43.35</phone>
      <email>sbranco@hopital-dcss.org</email>
    </contact>
    <investigator>
      <last_name>Antoine Angelergues</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Braun</last_name>
      <phone>0033 (0) 487 864 325</phone>
      <email>florence.braun@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit You, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Armoricain de radiothérapie, imagerie médicale et oncologie, CARIO</name>
      <address>
        <city>Plerin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude Vincent</last_name>
      <phone>+33257240243</phone>
      <email>a.vincent@bec22.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Claire Hardy-Bessard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Babarit</last_name>
      <phone>+ 33147111855</phone>
      <email>agnes.babarit@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Coraline Dubot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>St. Herblain CEDEX</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise SISTAC-DANTAL</last_name>
      <phone>0033240 67 99 05</phone>
      <email>Francoise.Sistac@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Berton-Rigaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre les Nancy_ Cedex</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chérifa KADOUCI</last_name>
      <phone>0033 383 59 85 51</phone>
      <email>c.kadouci@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Christine Kaminsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Jullemier</last_name>
      <phone>0033 142 116 663</phone>
      <email>estelle.JULLEMIER@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Leary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulm University Hospital Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Heike</last_name>
      <phone>+49 731 500 58523</phone>
      <email>heike.karl@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Fabienne Schochter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Griebsch</last_name>
      <phone>+49 (0) 351 458 4202</phone>
      <email>Christine.griebsch@ukdd.de</email>
    </contact>
    <investigator>
      <last_name>Pauline Wimberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mammazentrum Hamburg am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kassner Silke</last_name>
      <phone>0049 (0)40 44190 669</phone>
      <email>kassner@mammazentrum.eu</email>
    </contact>
    <investigator>
      <last_name>Felix Hilpert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gali Bortlik</last_name>
      <phone>972522358460</phone>
      <email>scurology@wmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tally Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical center</name>
      <address>
        <city>Jerusalem</city>
        <zip>POB 12000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noa Kamin</last_name>
      <phone>972-508909041</phone>
      <email>NOAKAMIN@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Shani Breuer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avital Diamant</last_name>
      <phone>09-7471041</phone>
      <email>avitaldi@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Mario Beiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Netta Beer</last_name>
      <phone>972-54-8913935</phone>
      <email>nettab@ziv.gov.il</email>
    </contact>
    <investigator>
      <last_name>Inbar Ben-Shachar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliana Bignotti</last_name>
      <phone>00390303996971</phone>
      <email>bignottieliana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Germana Tognon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Lecco- Ospedale A.Manzoni</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Corbetta</last_name>
      <phone>+ 0039 0341 489155</phone>
      <phone_ext>2155</phone_ext>
      <email>c.corbetta@asst-lecco.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Ardizzoia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Europeo di Oncologia (The European Institute of Oncology) (IEO)</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abbondanza Montinaro</last_name>
      <phone>+39 02 57489935</phone>
      <email>abbondanza.montinaro@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Nicoletta Colombo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Azienda Osc-IRCCS Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rossi</last_name>
      <phone>0039 0522 296858</phone>
      <email>andrea.rossi@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Bologna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano Umberto I</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michela Villa</last_name>
      <phone>0039 011 508 2682 / 508 5153</phone>
      <email>michelavilla.23@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Annamaria Ferrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center - Center for Uterine Cancer</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyeon Hyun</last_name>
      <phone>82319200856</phone>
      <email>75548@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Myong C Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bokeum Lee</last_name>
      <phone>82-31-787-8306</phone>
      <email>bokeum02@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yong Beom Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myoungsun Choi</last_name>
      <phone>82-2-6072-5198</phone>
      <email>iamyou3@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Jae-Weon Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Hyun Lee</last_name>
      <phone>010-2242-7786</phone>
      <email>hdkhappy@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jung-Yun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine - Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geum H Na</last_name>
      <phone>82-2-3010-3627</phone>
      <email>goldnah@naver.com</email>
    </contact>
    <investigator>
      <last_name>Yong-Man Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EunHwa Choi</last_name>
      <phone>82-10-8615-8787</phone>
      <email>eh77.choi@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Jeong-Won Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Hendriksen</last_name>
      <phone>+31 20 5668440</phone>
      <email>a.a.hendriksen@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Tromp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantalle Tilly</last_name>
      <phone>0031 (0)43-3871028</phone>
      <email>chantalle.tilly@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Roy Lalisang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>Postbus 9101, 6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy van Haaren - Vorstenbosch</last_name>
      <phone>+ 31 (024) 3655388</phone>
      <email>studies.onco@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Nelleke Ottevanger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milko Van Langen</last_name>
      <email>m.vanlangen@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Ingrid Boere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelika Wójtowicz</last_name>
      <phone>0048 725589826</phone>
      <email>angwojtowicz@uck.gda.pl</email>
    </contact>
    <investigator>
      <last_name>Dagmara Klasa-Mazurkiewicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny publiczny szpital kliniczny nr 1</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewelina Czech</last_name>
      <phone>+48 517211766</phone>
      <email>ewelinabond@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Wieslawa Bednarek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filipe Miguel Palatino Moreira</last_name>
      <phone>+351 916339533</phone>
      <phone_ext>51759</phone_ext>
      <email>96024@chln.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>Luis António Marques Costa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BIH of Omsk Region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <state>Omsk Oblast</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maksimenko</last_name>
      <phone>79620336767</phone>
      <email>asbogdalova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mikhail Dvorkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;VitaMed&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>10</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Basmanova</last_name>
      <phone>8-925-441-35-85</phone>
      <email>0793987@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Poddubskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leningrad regional oncology dispensa</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shagal Maria</last_name>
      <phone>79219781118</phone>
      <email>mashuta0302@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Olga Mikheeva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Salnikova</last_name>
      <phone>7 917 75 00 767</phone>
      <email>maria-salnikova@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Oleg Lipatov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia García</last_name>
      <phone>+ 34 981 955 679</phone>
      <email>silviagarciarubin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Fernando Cueva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. U. de Jaén</name>
      <address>
        <city>Jaén</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ruiz</last_name>
      <phone>0034 953220306</phone>
      <email>oncojaen@fibao.es</email>
    </contact>
    <investigator>
      <last_name>Fernando Galvez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Pérez</last_name>
      <phone>+34911915398</phone>
      <email>lperez_ec@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>María Merino Salvador</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Badalona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Rodriguez</last_name>
      <phone>+34 667 206 830</phone>
      <email>jrodriguez@igtp.cat</email>
    </contact>
    <investigator>
      <last_name>Margarita Romeo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. San Pedro de Alcántara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloisa Gómez</last_name>
      <phone>+ 34 927 621 612</phone>
      <email>eloisa.gomez@externos.salud-juntaex.es</email>
    </contact>
    <investigator>
      <last_name>Santiago González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellon</name>
      <address>
        <city>Castelló</city>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Herrero</last_name>
      <phone>+34 964 35 44 58</phone>
      <email>regina.romero@hospitalprovincial.es</email>
    </contact>
    <investigator>
      <last_name>Nuria Ruiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de San Chinarro-Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Morgades</last_name>
      <phone>+34917567984</phone>
      <phone_ext>4887</phone_ext>
      <email>pmorgades@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Arantzazu Barquín</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ruiz</last_name>
      <phone>+34 968 36 93 87</phone>
      <email>paula.ruiz@carm.es</email>
    </contact>
    <investigator>
      <last_name>Jeronimo Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merce Abad</last_name>
      <phone>(+34) 93 724 00 84</phone>
      <email>mabad@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Yolanda García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Bernal</last_name>
      <phone>+34 955013068</phone>
      <email>isabelb.onco.huvr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Purificación Estévez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maite Giralt</last_name>
      <phone>+34 96 124 41 88</phone>
      <email>Giralt_mail@gva.es</email>
    </contact>
    <investigator>
      <last_name>Ana Santaballa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCU Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Huércanos</last_name>
      <phone>+34 976 76 57 69</phone>
      <email>ihuercanos@iisaragon.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Yubero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuo Shu-Chun</last_name>
      <phone>886289667000</phone>
      <email>s8714224@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Sheng-mou Hsiao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital - Taipei Branch</name>
      <address>
        <city>Taipei City</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan-Ru Wang</last_name>
      <phone>+886975836979</phone>
      <email>b158.b158@mmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Long Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Hsun Chang</last_name>
      <phone>88628757826</phone>
      <email>whchang818@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Peng-Hui Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal non-profit enterprise &quot;Khmelnytskyi Regional Antitumor Center&quot; of Khmelnytskoyi Regional Council</name>
      <address>
        <city>Khmelnytskyi</city>
        <state>Khmelnytskyi Region</state>
        <zip>29009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetiana Melnychuk</last_name>
      <phone>+ 380673111500</phone>
      <email>mtvdoc@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Tetiana Piatnytska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peterborough City Hospital</name>
      <address>
        <city>Peterborough</city>
        <state>Cambridgeshire</state>
        <zip>PE3 9GZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri-Anne Baker</last_name>
      <phone>01733 677402</phone>
      <email>terri-anne.baker@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sarah Ayers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital (Wonford)</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Lawless</last_name>
      <phone>+44 (0)1392 402867</phone>
      <email>theresalawless@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Kate Scatchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Sanders</last_name>
      <phone>+ 02476 967147</phone>
      <email>Kay.sanders@uhcw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Lucy McAvan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catriona Cowan</last_name>
      <phone>0141 301 7217</phone>
      <email>Catriona.Cowan@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rosalind Glasspool</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital-Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gurpreet Singh</last_name>
      <phone>0203 46 56746</phone>
      <email>gurpreet.singh18@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Shanthini Crusz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Smith</last_name>
      <phone>020 3447 8025</phone>
      <email>amy.smith36@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rowan Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darshana Shah</last_name>
      <phone>2089156724</phone>
      <email>Darshana.Shah@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Susana Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Pearce</last_name>
      <phone>0161 446 3606</phone>
      <email>amy.pearce2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Gordon Jayson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-resistant</keyword>
  <keyword>Folate-receptor alpha expression</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Antibody-drug conjugate</keyword>
  <keyword>mirvetuximab soravtansine</keyword>
  <keyword>IMGN853</keyword>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

